What is Vertex Pharmaceuticals's other comprehensive income (loss)?

Vertex Pharmaceuticals (VRTX) reported other comprehensive income (loss) of $1.12B in Q3 2025.

How has Vertex Pharmaceuticals's other comprehensive income (loss) changed year-over-year?

Vertex Pharmaceuticals's other comprehensive income (loss) increased by 6.4% year-over-year, from $1.05B to $1.12B.

What does other comprehensive income (loss) mean?

The total change in equity resulting from non-operating items like currency fluctuations and pension adjustments.

Other Comprehensive Income (Loss)

Vertex Pharmaceuticals Other Comprehensive Income (Loss) increased by 29.6% to $1.12B in Q3 2025 compared to the prior quarter. Year-over-year, this metric grew by 6.4%, from $1.05B to $1.12B. This is a positive signal — higher values indicate stronger performance for this metric.

Analysis

StatementIncome Statement

SectionOther

CategoryOther

SignalHigher is better

VolatilityVolatile

First reportedQ1 2015

Last reportedQ3 2025

How to read this metric

An increase indicates positive impacts from external factors like currency gains or pension plan improvements, while a decrease suggests negative impacts from these items.

Detailed definition

This metric represents the total change in equity from non-owner sources, including items like foreign currency translat...

Peer comparison

Standardized as Other Comprehensive Income (OCI) across all public companies under GAAP/IFRS.

Metric ID: is_tmusz_other_comprehensive_income_loss

Historical Data

8 periods

	Q1 '23	Q2 '23	Q3 '23	Q4 '23	Q2 '24	Q3 '24	Q2 '25	Q3 '25
Value	$901.13M	$901.13M	$901.13M	$901.13M	-$3.59B	$1.05B	$863.70M	$1.12B
QoQ Change	—	+0.0%	+0.0%	+0.0%	-498.2%	+129.3%	-17.9%	+29.6%
YoY Change	—	—	—	—	-498.2%	+16.7%	+124.1%	+6.4%

Range-$3.59B – $1.12B

CAGR+13.2%

Avg YoY Growth-87.7%

Median YoY Growth+11.6%